Our product portfolio includes four major programs. The most advanced compound, lemuteporfin, is ready to proceed into a Phase 1/2 proof of concept trial. The other three are at various stages of preclinical development. Each compound in the portfolio is a new chemical entity with composition of matter, use, and formulation IP, targeting areas of medical need via a novel mechanism or therapeutic approach.